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Human skin ﬁbroblastCyclic phosphatidic acid (cPA) is a naturally occurring phospholipidmediator and an analog of the growth factor-
like phospholipid lysophosphatidic acid (LPA). cPA has a unique cyclic phosphate ring at the sn-2 and sn-3 posi-
tions of its glycerol backbone. We showed before that a metabolically stabilized cPA derivative, 2-carba-cPA, re-
lieved osteoarthritis pathogenesis in vivo and induced hyaluronic acid synthesis in human osteoarthritis
synoviocytes in vitro. This study focused on hyaluronic acid synthesis in human ﬁbroblasts, which retain mois-
ture and maintain health in the dermis. We investigated the effects of cPA and LPA on hyaluronic acid synthesis
in human ﬁbroblasts (NB1RGB cells). Using particle exclusion and enzyme-linked immunosorbent assays, we
found that both cPA and LPA dose-dependently induced hyaluronic acid synthesis. We revealed that the expres-
sion of hyaluronan synthase 2messenger RNA and protein is up-regulated by cPA and LPA treatment time depen-
dently. We then characterized the signaling pathways up-regulating hyaluronic acid synthesis mediated by cPA
and LPA in NB1RGB cells. Pharmacological inhibition and reporter gene assays revealed that the activation of the
LPA receptor LPAR1, Gi/o protein, phosphatidylinositol-3 kinase (PI3K), extracellular-signal-regulated kinase
(ERK), and cyclic adenosine monophosphate response element-binding protein (CREB) but not nuclear factor
κB induced hyaluronic acid synthesis by the treatment with cPA and LPA in NB1RGB cells. These results demon-
strate for the ﬁrst time that cPA and LPA induce hyaluronic acid synthesis in human skin ﬁbroblasts mainly
through the activation of LPAR1-Gi/o followed by the PI3K, ERK, and CREB signaling pathway.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
In 1992, cyclic phosphatidic acid (cPA) was originally isolated from
the myxoamoebae of a true slime mold, Physarum polycephalum [1].
Later, the presence of cPA was also found in mammalian tissues [2,3].carba-cPA; ChIP, chromatin im-
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akami-Murofushi).
. This is an open access article underAlthough the chemical formula of cPA is similar to that of lysophosphatidic
acid (LPA), cPAhas a quite unique structurewith a cyclic phosphate ring at
the sn-2 and sn-3positions of its glycerol backbone. These features provide
cPA with biological functions that are distinct from or opposite to those
of LPA [4–10]. To date, six LPA receptors, LPAR1–6, have been reported,
and cPA stimulates LPAR1–5. To explain the distinct biological functions
of cPA and LPAdespite their activation of the same receptors, we speculat-
ed the following possibilities: (1) cPA also activates cellular targets distinct
from those of LPA receptors, and (2) differences in the afﬁnity and efﬁcacy
of cPA and LPA to bind and activate LPA receptors and the combination
and expression level of LPA receptors in individual cells affect the ﬁnal
physiological output [11].
To date, we have found that cPAhas distinct biological activities such
as inhibiting autotaxin [6], suppressing the invasion and metastasis of
cancer cells [5–7], blocking nociceptive responses by primary afferent
C-ﬁbers [8], and attenuating ischemia-induced delayed neuronal cell
death in rat hippocampal CA1 regions [12]. Therefore, cPA is consideredthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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rodegeneration [8–12]. To develop this potential, we synthesized sever-
al metabolically stabilized derivatives of cPA. 2-Carba-cPA (2ccPA) is
one of the compounds in which phosphate oxygen is replaced with a
methylene group at the sn-2 position [6,10], and we showed that
2ccPA efﬁciently maintains numerous biological functions of cPA.
Recently, we found that 2ccPA induces hyaluronic acid synthesis in
human osteoarthritis synoviocytes [13]. Hyaluronic acid is a predomi-
nant component of the extracellular matrix and is involved in cellular
functions such as skin hydration, joint lubrication, and stimulation of
the migratory response of keratinocytes in wound healing [14,15].
Hyaluronic acid is synthesized by speciﬁc enzymes, hyaluronan
synthases 1, 2, and 3 (HAS1–3), and in skin dermis, HAS2 is shown to
be the predominant isoform [14]. TheHAS2promoter contains function-
al response elements for various transcription factors, including nuclear
factor κB (NFκB), cyclic adenosine monophosphate response element-
binding protein 1 (CREB1), speciﬁcity protein 1 (SP1), and signal trans-
ducer and activator of transcription 3 (STAT3) [16,17]. Some of these
factors are known effector molecules downstream of LPA stimulation
[18–20]. Upstream of these transcription factors, phosphatidylinositol-
3 kinase (PI3K) [16,21], extracellular-signal-regulated kinase (ERK)
[16,22], and Rho/Rho-associated kinase (ROCK) [22] are involved in
the signaling pathway of HAS2 protein expression. Furthermore, cPA
and LPA stimulate PI3K and ERK signaling [23–25], and LPA stimulates
Gi/o/PI3K–Akt/NFκB signaling [18].
This study focused on hyaluronic acid synthesis in human skin ﬁbro-
blasts. We showed that cPA and LPA increased HAS2 protein expression
and thereby induced hyaluronic acid synthesis in the cells. Moreover, we
showed that activation of LPAR1, Gi/o protein, PI3K, and ERK followed by
HAS2 transcriptional activation through CREB activation was important
for the HAS2-up-regulating signaling pathway mediated by cPA and LPA.
2. Materials and methods
2.1. Pharmacologic agents
cPA 18:1was chemically synthesized as previously described [26]. Bo-
vine serum albumin (BSA; fraction V, fatty acid-free) and 1-oleoyl-sn-
lysophosphatidic acid (LPA 18:1) were purchased from Sigma-Aldrich
(St. Louis, MO). LPA and cPAwere dissolved in phosphate-buffered saline
(PBS) containing 0.1% (w/v) BSA. The inhibitors Ki16425, U-73122 (Cay-
man Chemicals, MI), AG 490, CREB binding protein CBP–CREB interaction
inhibitor (Calbiochem, CA), U0126 (LC Laboratories, MA), Y-27632
(Sigma-Aldrich), LY294002 (Cell Signaling Technology, Inc., MA), and
BAY11-7082 (Focus Biomolecules, PA)weredissolved indimethyl sulfox-
ide and added to cells at a working concentration of 1 μM (AG 490) or
10 μM 30 min before the addition of cPA or LPA. Pertussis toxin (PTX;
List Biological laboratories, Inc., CA) was dissolved in PBS and added to
cells at a working concentration of 100 ng/ml 30 min before the addition
of cPA or LPA.
2.2. Cell culture and treatment
Normal human skin ﬁbroblasts, RIKEN original (NB1RGB) were pro-
vided by RIKEN BRC through the National Bio-Resource Project of the
Ministry of Education, Culture, Sports, Science and Technology, Japan.
The cells were cultured in minimum essential media-alpha containing
5.6 mM D-glucose (#11900-024, Life Technologies Corp., CA) supple-
mented with 10% fetal bovine serum (Biowest, FL), 0.2% NaHCO3, and
0.06% glutamine. Cells were grown at 37 °C in a humidiﬁed incubator
containing 5% CO2. For all the experiments, human ﬁbroblasts were
seeded into a 6-well plate (5 × 103 cells/well) and incubated for 8 h
with culturemedia containing 10% fetal bovine serum. As it has been re-
ported that hyaluronic acid production was generally higher in
subconﬂuent compared with conﬂuent cultures [27], we seeded cells
in very low density to detect clearly the effects of cPA and LPA onhyaluronic acid synthesis. The cells were then subjected to serum starva-
tion for 16 hwith serum-free minimum essential media-alpha. All subse-
quent incubations were performed under serum-starved conditions.
2.3. Particle exclusion assay
Particle exclusion assay was carried out according to a protocol de-
scribed previously [28]. Brieﬂy, sheep erythrocytes (Nippon Biotest Lab-
oratories Inc., Tokyo, Japan) were ﬁxed in 1.5% formaldehyde in calcium-
and magnesium-free PBS (CMF-PBS) overnight at 37 °C, washed with
CMF-PBS 4 times, reconstituted in CMF-PBS (5 × 108 cells/ml) and
used for the particle exclusion assay. For the assay, serum-starved ﬁbro-
blasts (3 × 104 cells/6 cm-dish) were incubated with 3 μM cPA or LPA in
serum-free culture media for 24 h. And cells were treated for 30 min at
37 °C in the absence or presence of 16 units/ml of hyaluronidase
“Amano” from Streptomyces hyalurolyticus (Amano enzyme Inc., Tokyo,
Japan) in serum-free media as described previously [29]. Then, ﬁxed
sheep red blood cells (1 × 107 cells) in 3 ml PBS containing 0.1% BSA
were added. The red blood cells were allowed to settle for approximately
10 min. The ﬁbroblasts were then observed and photographed with a
Nikon ECLIPSE TS 100 phase-contrast microscope (NIKON Corp., Tokyo,
Japan). The hyaluronic acid pericellular coat to cell area ratios weremea-
sured using ImageJ software [30].
2.4. Determination of hyaluronic acid concentration in culture superna-
tants of ﬁbroblasts
To study the effects of cPA or LPA on human ﬁbroblast hyaluronic
acid synthesis, we removed the serum-free media, then we preincubat-
ed serum-starved cells for 30 min with or without inhibitors for signal
transduction pathways or transcription factors, and then vehicle or
3 μM cPA or LPA was added. Thereafter, the cells were cultured for 24
to 72 h. The cells were counted and media were collected to measure
hyaluronic acid using an enzyme-linked immunosorbent assay kit
(R&D Systems, Inc., MN) according to the manufacturer's instructions.
The obtained datawere analyzed and converted to concentration values
(ng/1 × 103 cells) or (ng/ml) using the analysis software GraphPad
Prism (GraphPad Software, San Diego, CA).
2.5. Agarose-gel electrophoresis of hyaluronic acid
Serum-starved cells were incubated with vehicle, 3 μM cPA or LPA
for 72 h, then 20 ml media were collected and concentrated to 30 μl
using centrifugal ﬁlters (Amicon Ultra-30 K membrane, Millipore,
MA). Agarose-gel electrophoresis of concentrated media from vehicle,
3 μM cPA or LPA treated cells was performed as described by Mary K.
Cowman et al. [31,32]. Concentrated media (30 μl/lane) and 15 μl/lane
of DNA marker (#Marker 6, Nippon gene Co., Ltd., Tokyo, Japan) were
loaded on the gel. And electrophoresis was carried out at a constant
voltage of 20V for 30min and then 50V for 1 h. Then the gelwas stained
with 0.005% Stains-All (Sigma-Aldrich) in 50% ethanol/water for 16 h.
Destaining was done with 10% ethanol/water. Then, a strong blue
band was detected as hyaluronic acid band [33]. The gel image was ob-
tained using a GE Healthcare ImageQuant LAS 4000.
2.6. Western blot analysis
Cells were collected and subjected to western blot analysis to detect
phospho-ERK (pERK), ERK, HAS2, and β-actin expressions. Proteins
were separatedwith sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and transferred to an Immobilon-P Transfer Membrane
(Millipore). Using anti-HAS2 (1:500 dilution, #HAS2 (H-60): sc-66916,
Santa Cruz Biotechnology, Inc., CA), anti-β-actin (1:1000 dilution, Medi-
cal & Biological Laboratories Co., Ltd., Aichi, Japan), anti-pERK or anti-ERK
(1:1000 dilution, Cell Signaling Technology, Inc., MA) antibodies and
horseradish peroxidase-conjugated anti-rabbit immunoglobulin G
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formed immunodetection using “Can Get Signal” immunoreaction en-
hancer solutions (TOYOBO Co., LTD., Osaka, Japan) and an enhanced
chemiluminescence system (Bio-Rad Laboratories, Inc., CA).
2.7. RNA isolation and real-time polymerase chain reaction (PCR)
Total RNA was extracted from human ﬁbroblasts using Isogen re-
agent (Nippon gene) as a template for subsequent complementary
DNA synthesis with oligo dT primers using an Omniscript RT Kit
(Qiagen, CA). Messenger RNA (mRNA) levels were quantiﬁed using an
ABI 7300 real-time PCR machine (Foster City, CA) and SYBR Premix Ex
Taq II (Takara Bio Inc., Shiga, Japan). Gene-speciﬁc primer sets for
HAS1 were used as previously reported [34], as were primers for β-
actin, LPAR1, LPAR4, LPAR5, LPAR6, p2y5, and p2y10 [12].
The following primer sets were used: HAS2, 5′-GCCTCATCTGTGGAGA
TGGT-3′ (F) and 5′-ATGCACTGAACACACCCAAA-3′ (R); LPAR2, 5′-GAGG
CCAACTCACTGGTCA-3′ (F) and 5′-GGCGCATCTCAGCATCTC-3′ (R);
LPAR3, 5′-GAAGCTAATGAAGACGGTGATGA-3′ (F) and 5′-AGCAGGAACC
ACCTTTTCAC-3′ (R); and GPR87, 5′-AAATCCAGCAGGCAATTCAT-3′ (F)
and 5′-CCCTGATGCTCTGGTTATGTT-3′ (R).
The data were analyzed using the delta cycle threshold method. The
expression level of each LPA receptor was normalized to β-actin expres-
sion as previously described [12,35]. The expression levels were nor-
malized to those of LPAR1 and expressed in terms of mean± SE values.
2.8. Reporter gene assay
Reporter gene assay was performed as described [36]. Brieﬂy, cells
were transfected with phospho-cyclic adenosine monophosphate re-
sponse element (pCRE)-secreted alkaline phosphatase (SEAP) vector
(Mercury™ pathway proﬁling system, Clontech Laboratories Inc., CA)
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer's instructions. Then, after 24 h of incubation, cells were
seeded into 6-well plates and incubated for 8 h followed by 16 h of
serumstarvation. Vehicle or 3 μMcPA or LPAwas added, and cell culture
media were collected after 4, 8, 12, and 24 h of incubation. SEAP activi-
ties in culture media were measured using a Great EscAPe SEAP chemi-
luminescence kit (Clontech Laboratories Inc.). The SEAP activities were
calculated as the ratio of SEAP activity of ligand-stimulated cells to
that of vehicle controls.Fig. 1. Particle exclusion assay. Particle exclusion assay was performed to visualize hyaluronic
phatidic acid (cPA) or lysophosphatidic acid (LPA) for 24 h. Then cells were incubated with or2.9. Statistical analysis
All values are reported as means ± standard error. The data were
analyzed using the Student's t-test. A P value less than 0.05 was consid-
ered statistically signiﬁcant.
3. Results and discussion
3.1. cPA and LPA induce hyaluronic acid synthesis
Hyaluronic acid synthesis is important to the health and function of
joints, eyes, and skin. However, hyaluronic acid synthesis declines with
age andmaintenance and regulation of the function of these organs are
gradually lost. We have revealed that a metabolically stabilized cPA de-
rivative, 2ccPA, remarkably induces hyaluronic acid synthesis in human
osteoarthritis synoviocytes. This compound also relieves osteoarthritis
pathogenesis in vivo [13]. Because skin aging is mainly triggered by
loss of hyaluronic acid in the dermis,we focused on hyaluronic acid syn-
thesis in human skin ﬁbroblasts.
We initially studied the effects of cPA and LPA on hyaluronic acid
synthesis in human ﬁbroblasts, NB1RGB cells. Particle exclusion assay
was used to detect pericellular hyaluronic acid coats and we observed
an obvious increase in pericellular hyaluronic acid coat formation after
cPA and LPA stimulation (Fig. 1). And these coats were removed after
hyaluronidase treatment, suggesting that the coats surrounding the
cells were composed by hyaluronic acid but not by other extracellular
matrix components. The pericellular coat/cell area of cPA- or LPA-
treated cells was approximately 3-fold higher than that of vehicle-
treated cells (Table 1).
To measure hyaluronic acid concentration in media, we performed
enzyme-linked immunosorbent assay. cPA treatment increased the
amount of hyaluronic acid with incubation time (Fig. 2A). Before addi-
tion of cPA and LPA, we measured hyaluronic acid concentration in
media (i.e. 0 time), but we could not detect any hyaluronic acid in cul-
turemedia. After 72 h, 3 μMcPA and LPAwas themost effective concen-
tration among various doses (0.1–3 μM). To assess the dose dependency
of cPA and LPA, we treated NB1RGB cells with various concentrations of
cPA or LPA. As shown in Fig. 2B, the treatment with cPA or LPA for 72 h
stimulated hyaluronic acid synthesis in a bell-shaped, dose-dependent
manner. At the most effective dose of 3 μM of cPA or LPA, each concen-
tration of hyaluronic acid was approximately 2.7 or 4.7 times higheracid coats surrounding cells. NB1RGB cells were treated with vehicle or 3 μM cyclic phos-
without hyaluronidase for 30 min.
Table 1
Hyaluronic acid pericellular coat/cell area.
Treatment Area ratioa
Vehicle 1.2 ± 0.1
cPA 3.3 ± 0.2
LPA 3.5 ± 0.2
a Values are means ± standard error (SE) (n = 20).
Fig. 2. Effects of cPA and LPA on the synthesis of hyaluronic acid. (A) NB1RGB cells were
incubatedwith 0.3, 1, or 3 μMcPA for the time indicated. The concentrations of hyaluronic
acid in culture media were determined with enzyme-linked immunosorbent assay
(ELISA). The data represent mean ± SE values from triplicate independent experiments
(*P b 0.001 vs. the vehicle-treated group). (B) NB1RGB cells were incubated with vehicle
or various concentrations of cPA or LPA for 72 h. The concentrations of hyaluronic acid in
culture media were determined with ELISA. The data represent mean ± SE values from
quadruplicate independent experiments (*P b 0.001 vs. the vehicle-treated group). (C)
Electrophoresis of hyaluronic acid on 0.5% agarose-gel. Lane 1: DNA marker; lane 2: con-
centrated medium from vehicle treated cells, lane 3: concentrated medium from 3 μM
cPA treated cells, and lane 4: concentrated medium from 3 μM LPA treated cells.
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produced at the plasmamembrane, however other glycosaminoglycans
are synthesized in the Golgi apparatus [37]. To verify whether the ef-
fects of cPA and LPA on hyaluronic acid synthesis are speciﬁc or not,
we examined the effect of cPA and LPA on the synthesis of glycosamino-
glycan. Serum-starved cells were incubated for 72 h with vehicle, 3 μM
of cPA or LPA and glycosaminoglycan were measured with Blyscan Sul-
fated Glycosaminoglycan Assay kit (Biocolor Ltd., Northern Ireland,
U.K.). We found that cPA and LPA did not increase the synthesis of
other glycosaminoglycan under the experimental conditions (data not
shown). So, results suggested that the effects of cPA and LPA were spe-
ciﬁc to hyaluronic acid synthesis.
Moreover, we measured hyaluronic acid mass synthesized after cPA
or LPA stimulation. Staining with Stains-All [31–33], a strong blue band
of hyaluronic acid was detected and the hyaluronic acid mass wasmea-
sured as N2 × 106 Da (Fig. 2C). These results indicate that cPA and LPA
similarly stimulate high molecular weight hyaluronic acid synthesis in
human ﬁbroblasts. Hyaluronic acid has several functions depending
on its molecular weight. The low molecular weight hyaluronic acid
(b0.5 × 106 Da) was reported to induce inﬂammatory responses in in-
ﬂammatory cells [38]. Here, we show that cPA and LPA stimulate
NB1RGB to induce high molecular weight hyaluronic acid synthesis.
To investigate whether cPA and LPA affect HAS1–3 expression, we
ﬁrst examined HAS1–3mRNA expression levels for 72 h by using quan-
titative real-time PCR. As shown in Fig. 3A, treatment with 3 μM of cPA
and LPA increasedmRNA expression of HAS2, a predominant isoform in
skin dermis, with a maximum increase between 4 and 8 h. Conversely,
HAS1 mRNA expression did not change in the presence of cPA and
LPA (Fig. 3A). We could not detect HAS3 mRNA expression in NB1RGB
cells (data not shown). It has been reported that HAS2 gene and its nat-
ural antisense RNA HAS2-AS1 exhibited coordinated expression and
HAS2-AS1 stabilizes or augments HAS2 mRNA expression via RNA/
mRNA heteroduplex formation [39]. Coordinated temporal proﬁles of
transcriptional induction of HAS2-AS1 and HAS2 were observed in bi-
phasic response to stimulation with interleukin-1β. On the other
hand, transforming growth factor-β1 up-regulated both HAS2-AS1
and HAS2 transcripts for 72 h. In our study, we did not analyze HAS2-
AS1 expression and the contribution of HAS2-AS1 expression for HAS2
mRNA expression stimulated by cPA- and LPA-treatment remains un-
clear, but we observed that HAS2 mRNA expression stimulated by cPA
and LPA increased between 4 and 8 h and then decreased gradually af-
terwards. These results indicate that cPA and LPA treatment increases
HAS2 mRNA expression and, in turn, hyaluronic acid synthesis and se-
cretion into culture media.
We examined the protein expression of HAS2withwestern blot anal-
ysis (see Fig. 3B). As shown in Fig. 3C, HAS2 protein expressionwas time-
dependently increased for 72 h with 3 μM cPA and LPA treatment. These
data show that the signiﬁcant increase of hyaluronic acid in culturemedia
mediated by cPA and LPA is due to up-regulation of HAS2mRNA and pro-
tein expression. Although LPA stimulated HA synthesis much higher than
cPAdid (Fig. 2B), LPAup-regulatedHAS2mRNAandprotein expression at
the same level with cPA. So far, 4 kinds of covalent modiﬁcation of HAS2
protein have been reported [37,40–42]. 1) Phosphorylation of HAS2 at
threonine 110 by adenosine monophosphate activated protein kinase
(AMPK) decreases its activity [43], 2) O-GlcNAcylation at serine 221 of
HAS2 is involved in its stabilization [44], 3)Mono-ubiquitination at lysine
190 of HAS2 is required for dimer formation and its activity [45], and 4)
Fig. 3. Effects of cPA and LPAon the expression of hyaluronan synthase (HAS) 1 and 2mes-
senger RNA (mRNA) and HAS2 protein. (A) NB1RGB cells were incubated with 3 μM cPA
(open or closed circles) or LPA (open or closed triangles) for the time indicated. mRNA
levels of HAS1 (dashed line) and HAS2 (solid line) were determined with quantitative
real-time polymerase chain reaction (PCR). The data represent the mean ± SE values
from triplicate independent experiments (*P b 0.005 and **P b 0.001 vs. time 0). (B)
NB1RGB cells were incubated with vehicle or 3 μM cPA or LPA for the time indicated. Pro-
tein levels of HAS2 and β-actin were determined with western blot analysis. (C) Expres-
sion levels of HAS2 and β-actin were determined using a densitometer, and the HAS2/β-
actin ratio was calculated and normalized to cells without any treatment at time 0. The
data represent mean ± SE values from triplicate independent experiments (*P b 0.05 vs.
the vehicle-treated group).
Fig. 4. Expression of LPA receptors (LPARs) in human ﬁbroblasts. Total RNAwas extracted
fromNB1RGB cells, and the expression level of each LPARwas determined using quantita-
tive real-time PCR. The expression levelswere normalized to those of LPAR1 and expressed
in terms of mean ± SE values (n= 3).
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ferent from that modiﬁed by AMPK, increases its activity [46]. Taking
those results into account, cPA and LPA might have different post-
translational regulation of HAS2 activity, and as a result the cPA and LPA
showed different levels of hyaluronic acid synthesis.
3.2. cPA and LPA increase HAS2 protein expression by activating CREB tran-
scription factor
To explore which signaling pathways stimulate hyaluronic acid syn-
thesis in response to cPA and LPA,we ﬁrst investigated the expression ofLPA G protein-coupled receptors in NB1RGB cells. As shown in Fig. 4,
quantitative real-time PCR analysis showed that NB1RGB cells strongly
expressed LPAR1, which induces cellular signaling through three G pro-
teins, Gi/o, Gq, and G12/13 [47].
To investigate the role of LPAR1 on the regulation of hyaluronic acid
synthesis, we used Ki16425, an LPA receptor antagonist that speciﬁcally
acts on LPAR1 and LPAR3. As shown in Fig. 5, the cPA- and LPA-induced
increases in hyaluronic acid synthesis were partially suppressed by
Ki16425 treatment, suggesting the involvement of LPAR1 in their signal-
ing pathways. We then investigated whether the PTX-sensitive Gi/o-
dependent pathwaywas involved in cPA- and LPA-mediated hyaluronic
acid synthesis. When cells were pretreated with 100 ng/ml PTX before
cPA or LPA stimulation, cPA- and LPA-mediated hyaluronic acid synthe-
sis was inhibited by PTX. This result suggests that cPA and LPA up-
regulate hyaluronic acid synthesis and HAS2 mRNA expression via the
LPAR1-mediated Gi/o signaling pathway.
To gain more insight into the signaling pathways involved in the
stimulation of hyaluronic acid synthesis in response to cPA and LPA
via LPAR1, we used several speciﬁc inhibitors of downstream signaling
molecules at non-cytotoxic concentrations conﬁrmed by counting the
cell number after 72 h of incubation (data not shown). The phospholi-
pase C-γ inhibitor U73122 did not inhibit the effects of cPA and LPA,
suggesting that the downstream signaling pathway of LPAR1 is not Gq/
phospholipase C-γ dependent (Fig. 5). The hyaluronic acid synthesis
stimulated by cPA and LPA was suppressed by PI3K inhibitor
YL294002, ERK1/2 inhibitor U0126, and ROCK inhibitor Y27632, where-
as the hyaluronic acid synthesis in vehicle-treated cells was also sup-
pressed by YL294002, U0126, and Y27632. ERK and PI3K signaling
pathwayswere reported to benecessary for the regulation of hyaluronic
acid synthesis by platelet-derived growth factor-BB in human skin ﬁ-
broblasts [16]. ROCK signaling and nuclear translocation of pERK have
also been linked to the regulation of hyaluronic acid synthesis [22].
Therefore, the activity of these inhibitors on cPA- and LPA-stimulated
hyaluronic acid synthesis might be due to the decline of potential
hyaluronic acid synthesizing capability in NB1RGB cells. Although it is
clear that cPA and LPA activate LPAR1 and the Gi/o signaling pathway,
cPA and LPA might also stimulate hyaluronic acid synthesis via PI3K,
ERK, and ROCK signaling pathways.
The binding sites for STAT3, NFκB, and CREB are located in the pro-
moter region of HAS2 [16]. We investigated the effects of AG490
(STAT3 inhibitor), Bay11-7082 (NFκB inhibitor), and CBP–CREB interac-
tion inhibitor on hyaluronic acid synthesis via HAS2 mRNA expression.
As shown in Fig. 6, Bay11-7082, AG490, and CBP–CREB interaction in-
hibitor suppressed hyaluronic acid synthesis with vehicle treatment.
However, the addition of Bay11-7082 and AG490 did not suppress
cPA- and LPA-stimulated hyaluronic acid synthesis. From these results,
we excluded the possibility of the involvement of NFκB and STAT3 in
the cPA- and LPA-stimulated HAS2 mRNA expression signaling
Fig. 5.Effects of signal transduction inhibitors on cPA- and LPA-induced hyaluronic acid synthesis. (A) NB1RGB cellswere pretreatedwith orwithout 10 μMofKi16425, U73122, YL294002,
U0126, and Y27632 or 100 ng/ml of pertussis toxin for 30 min. Then, the cells were incubated with vehicle or 3 μM cPA or LPA for 72 h. The concentrations of hyaluronic acid in culture
media were determined using ELISA. The data represent mean ± SE values from triplicate independent experiments (*P b 0.05 and **P b 0.001 vs. dimethyl sulfoxide [DMSO]).
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signiﬁcantly suppressed cPA- and LPA-stimulated hyaluronic acid syn-
thesis. These results indicate that the CREB signaling pathway but not
the STAT3 and NFκB signaling pathways has a major role in cPA- and
LPA-induced hyaluronic acid synthesis. Since we found that the treat-
ment with cPA and LPA increased HAS2 mRNA expression at 6 h
(Fig. 3A), we investigated the effects of the CBP–CREB interaction inhib-
itor on cPA- and LPA-stimulatedHAS2mRNA expression at 6 h. Approx-
imately 78% and 74% of cPA- and LPA-stimulated HAS2 mRNA
expression were inhibited by CBP–CREB interaction inhibitor treatment
(Fig. 7). These results were in good agreement with those of our phar-
macological inhibition assay (Fig. 6).
Moreover, we examinedwhether ERKactivation in skinﬁbroblasts is
induced by cPA and LPA stimulation. After cPA and LPA stimulation, ERK
activity (pERK/total ERK) was increased in a time-dependent manner,
with amaximumbetween 5 and 30min (Fig. 8). These resultswere con-
sistent with those of previous studies in other cell lines [23,24].Fig. 6. Effects of signal transcription factor inhibitors on cPA- and LPA-induced hyaluronic
acid synthesis. NB1RGB cells were pretreated with or without 10 μM Bay11-7082, 1 μM
AG490, or 10 μM cyclic adenosine monophosphate response element binding protein
(CREB)-binding protein (CBP)–CREB interaction inhibitor for 30 min. Subsequently, the
cells were incubated with vehicle, 3 μM cPA or LPA for 72 h. The concentrations
of hyaluronic acid in culture media were determined with ELISA. The data represent
mean ± SE values from triplicate independent experiments. DMSO, dimethyl sulfoxide.Previously, it has been reported that ErbB2–ERK signaling activated
hyaluronic acid synthesis via phosphorylation of HAS2 and the stimula-
tion decreased the molecular size of hyaluronic acid [46]. Although cPA
and LPA increased the high molecular size of hyaluronic acid, cPA- and
LPA-induced ERK phosphorylation might phosphorylate HAS2.
Finally, to determine the effect of cPA and LPA on CRE-dependent
transcription, the activation of cyclic adenosine monophosphate-
dependent gene transactivation in NB1RGB cells was examined using
pCRE-SEAP, a reporter construct consisting of three copies of the CRE-
binding sequence driving the expression of the SEAP gene. As shown in
Fig. 9, cPA and LPA transactivated SEAP activity in a time-dependentman-
ner. Taken together, these results suggest that cPA- and LPA-induced
hyaluronic acid synthesis is a consequence of HAS2 mRNA up-
regulation mediated via LPAR1/Gi/o followed by the PI3K, ERK, ROCK,
and CREB cascades in NB1RGB cells as shown in Scheme 1. cPA and LPA
ﬁrst stimulate the LPAR1/Gi/o pathway, and PI3K and ERK are subsequent-
ly activated. Although PI3K was reported to activate ERK signaling in
MDA-MB-231 breast cancer cells [24], whether ERK activation in human
skin ﬁbroblasts ismediated directly or indirectly by PI3K remains unclear.
Moreover, the ROCK family of Rho-associated protein kinases is reported-
ly essential for F-actin assembly, and phosphorylation of coﬁlin and actin
assembly caused translocation of pERK in the nucleus [22]. LPAR1Fig. 7. Effects of CBP–CREB interaction inhibitor on cPA- and LPA-stimulated HAS2mRNA
expression. Serum-starved NB1RGB cells were preincubated with or without 10 μM CBP–
CREB interaction inhibitor for 30min. Then cells were incubatedwith vehicle, 3 μMcPA or
LPA for 6 h, and mRNA levels of HAS2 were determined with qPCR. HAS2 mRNA levels of
cPA- or LPA-treated cells at 6 hwere expressed as 100%. The data represent themean± SE
values from triplicate independent experiments (*P b 0.001 vs. DMSO).
Fig. 8. Effects of cPA and LPA on extracellular-signal-regulated kinase (ERK) phosphoryla-
tion. (A)NB1RGB cellswere incubatedwith 3 μMcPAor LPA for the time indicated. Protein
levels of phospho-ERK (pERK) and total ERK were determinedwith western blot analysis.
(B) The expression levels of pERK and total ERK were determined using a densitometer,
and the pERK/ERK ratio was calculated and normalized to cells without any treatment at
time 0. The data represent mean ± SE values from triplicate independent experiments
(*P b 0.05, **P b 0.01 and ***P b 0.001 vs. time 0).
Scheme1. Schematicmodel for hyaluronan synthase 2 (HAS2) gene expression via activa-
tion of cyclic adenosinemonophosphate response element-binding protein (CREB). Cyclic
phosphatidic acid (cPA) and lysophosphatidic acid (LPA) interact with LPAR1, which acti-
vates Gi/o then mediates the activation of phosphatidylinositol-3 kinase (PI3K) and
extracellular-signal-regulated kinase (ERK). Activation of ROCK leads to ERK activation,
too [22]. Activated ERK increases the activity of HAS2 via HAS2 protein phosphorylation
[46]. Activated CREB stimulates the transcriptional activation of the HAS2 gene.
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tion was reported to be involved in LPA receptor/G12-dependent activa-
tion of the CREB pathway in ovarian cancer cells [20]. Therefore, ERK
may also be activated via LPAR1/G12/13-ROCK signaling. Finally, activated
ERK activates CREB, inducing HAS2 mRNA transcription.
Hyaluronic acid has a critical role in the physiology and pathology of
several mammalian tissues. Increase of hyaluronic acid is involved in in-
ﬂammation, cancer, ﬁbrosis and diabetes, and decrease of hyaluronic
acid is related to joint disorders. Previously, it has been reported that
LPA level was increased in chronic hepatitis C patients, andwas positive-
ly correlated with serum hyaluronic acid amount [48]. And LPAR1Fig. 9. Effects of cPA and LPA on cyclic adenosinemonophosphate-responsive gene activa-
tion via CREB. Cells transiently transfected with phospho-cyclic adenosine
monophosphate response element-secreted alkaline phosphatase (pCRE-SEAP) expres-
sion vector were treated for 4, 8, 12, and 24 h with vehicle or 3 μM cPA or LPA. Relative
SEAP activity is shown and fold inductions are calculated in reference to values in the
vehicle-treated group. The data represent mean ± SE values from triplicate independent
experiments (*P b 0.05 and **P b 0.01 vs. vehicle-treated group).antagonist inhibited lung ﬁbrosis in the mouse bleomycin model [49].
Here, we observed that LPA up-regulated hyaluronic acid via LPAR1 stim-
ulation, suggesting that increased LPAmight stimulate LPAR1 and caused
hyaluronic acid accumulation. However, our data were obtained using
skin ﬁbroblasts, therefore, the relationship between increased LPA and
hyaluronic acid accumulation in the diseases remains unresolved.
Our ﬁndings on the up-regulation of dermis hyaluronic acid synthe-
sis by cPA and LPA offer useful information formaintaining the health of
the skin. So far, the correlations between cPA and the diseases are un-
known, thus, cPA would be available as a therapeutic agent for the con-
trol of aging of skin.
4. Conclusion
Hyaluronic acid synthesis is important for themaintenance of healthy
joint, eye, and skin functioning. 2ccPA, a cPA derivative, increases
hyaluronic acid synthesis in human osteoarthritis synoviocytes [13]. In
this study, we focused on the maintenance of skin health and examined
the effect of cPA and LPA on hyaluronic acid synthesis by using human
skin ﬁbroblasts. The study revealed the signaling pathways involved in
the stimulation of hyaluronic acid synthesis in response to cPA and
LPA. This is the ﬁrst report that cPA and LPA induce hyaluronic acid syn-
thesis as a consequence of HAS2 mRNA up-regulation in human skin ﬁ-
broblasts mainly through activation of LPAR1/Gi/o followed by PI3K,
ERK, ROCK, and CREB signaling (see Scheme 1). This study suggests
that cPA could suppress the age-related decline of hyaluronic acid syn-
thesis in the skin.
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